Leukaemia Drug Given the Green Light
FDA declined a marketing application for the drug in 2005.
The US Food and Drug Administration has given the green light to Talon Therapeutics' orphan drug Marqibo to treat a rare type of leukaemia after the drug was fast tracked through the agency's accelerated approval programme.
Specifically, Marqibo (vincristine sulphate liposome injection) will treat the rapidly progressing type of blood and bone marrow cancer, known as Philadelphia chromosome negative acute lymphoblastic leukaemia, indicated for patients that have relapsed two or more times or failed at least two other therapies.
Hide Comments (0)
Editor's Note: As of February 29, 2024, commenting privileges on reason.com posts are limited to Reason Plus subscribers. Past commenters are grandfathered in for a temporary period. Subscribe here to preserve your ability to comment. Your Reason Plus subscription also gives you an ad-free version of reason.com, along with full access to the digital edition and archives of Reason magazine. We request that comments be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of reason.com or Reason Foundation. We reserve the right to delete any comment and ban commenters for any reason at any time. Comments may only be edited within 5 minutes of posting. Report abuses.
Please
to post commentsMute this user?
Ban this user?
Un-ban this user?
Nuke this user?
Un-nuke this user?
Flag this comment?
Un-flag this comment?